Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers in Idiopathic Juvenile Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02343770
Recruitment Status : Unknown
Verified September 2015 by University Hospital, Montpellier.
Recruitment status was:  Recruiting
First Posted : January 22, 2015
Last Update Posted : September 7, 2015
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
Juvenile idiopathic arthritis (JIA) is the most common form of arthritis in children. The etiology is unknown. Several types of arthritis fall under the JIA heading. Oligoarticular JIA with antinuclear antibodies affects about half of all children. There 's no specific markers. Our purpose is to identify new markers in this pathology. The ProtoArray®Human Protein Microarray allows rapid and efficient detection of protein interaction using a suitable protein or small molecule probe. The investigators hope so detect novel potential autoantigen biomarkers specific in JIA.

Condition or disease Intervention/treatment Phase
Idiopathic Juvenile Arthritis Other: blood sample for identifying biomarkers Not Applicable

Detailed Description:
We select 10 patients with inclusion criteria and 10 controls. We analyse their blood sample (5ml). The ProtoArray® Microarray allows to detect novel protein-protein interactions, to rapidly perform serum profiling using a sensitive method to detect potential autoantigen biomarkers. The ProtoArray® Human Protein Microarray is a high-density protein microarray containing thousands of purified human proteins for protein interaction screening.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive.
Study Start Date : June 2015
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: idiopathic juvenile arthritis
blood sample
Other: blood sample for identifying biomarkers
control
blood sample
Other: blood sample for identifying biomarkers



Primary Outcome Measures :
  1. identification of specific autoantigen biomarkers [ Time Frame: 1 day ]
    Identify blood sampling biomarkers of juvenile idiopathic arthritis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for experimental group :

  • child age from 2 to 16 years
  • Oligoarticular JIA with antinuclear antibodies
  • with or without uveitis

Exclusion criteria for experimental group :

  • immunosuppressive and biological therapy

Inclusion Criteria for control group :

  • child age from 2 to 16 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02343770


Locations
Layout table for location information
France
Cardiology paediatric consultation, Arnaud de Villeneuve Hospital Recruiting
Montpellier, France, 34295
Contact: Aurelia CARBASSE, MD    +33 4 67 33 66 34    a-carbasse@chu-montpellier.fr   
Principal Investigator: aurelia carbasse, MD         
Sponsors and Collaborators
University Hospital, Montpellier
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT02343770    
Other Study ID Numbers: 9355
First Posted: January 22, 2015    Key Record Dates
Last Update Posted: September 7, 2015
Last Verified: September 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases